Corcept Therapeutics CORT -4.84% Get Free Report has outperformed the market over the past 20 years by 7.21% on an annualized ...

Corcept Therapeutics (CORT) closed the last trading session at $91.93, gaining 64.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Corcept Therapeutics Incorporated’s CORT share price has surged by 82.59%, which has investors questioning if this is right ...

Corcept Therapeutics Incorporated’s CORT share price has dipped by 7.02%, which has investors questioning if this is right ...

Corcept Therapeutics CORT over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have ...

Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a type of ovarian cancer without the disease getting worse in a late-stage trial ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...

Truist analyst Joon Lee raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $76 and keeps a Buy rating on the shares.

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

Prudential Financial Inc. decreased its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 2.5% in the fourth quarter, according to the company in its most recent Form 13F ...